Clinical trials: Apatinib, open to volunteers
Gestational Trophoblastic Neoplasia
Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia
The purpose of this study is to evaluate the efficacy and safety of camrelizumab and apatinib as combination therapy in patients with ultra high-risk (Cohort A) and high-risk chemo-refractory or relapsed (Cohort B) gestational…
- Trial name
- NCT05139095
- Testing
- Camrelizumab plus apatinib CohortA, Camrelizumab plus apatinib Cohort B
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
HCC
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage.
- Trial name
- NCT07589244
- Testing
- VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
Breast Neoplasms, Advanced Breast Cancer
Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer
This is a single-arm, open-label, phase 2 clinical trial using a stratified Simon minimax two-stage design. The study aims to evaluate the efficacy and safety of low-dose apatinib (250 mg daily) combined with physician-selected…
- Conditions
- Breast Neoplasms, Advanced Breast Cancer, HER2-positive Breast Cancer, HER2-low Breast Cancer
- Trial name
- NCT07907354
- Testing
- Apatinib mesylate, Physician's choice chemotherapy
- Volunteers
- 56 people
- Sponsor
- Yunnan Cancer Hospital
Gastric Cancer (Diagnosis)
Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis
This clinical study is designed to evaluate a combined treatment approach in adults with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has spread to the peritoneum (peritoneal metastasis), as confirmed…
- Trial name
- GCPM-HIPEC (NCT07904442)
- Testing
- Retlirafusp alfa + nab-paclitaxel + apatinib, HEPIC
- Volunteers
- 32 people
- Sponsor
- Anhui Provincial Cancer Hospital
Breast Cancer
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis.
- Trial name
- NCT06992336
- Testing
- Apatinib, Camrelizumab, Capecitabine
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Malignant Neoplasms of Digestive Organs
A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study
This study is to evaluate the efficacy of the LM-302 Combination With Other Therapies in patients with CLDN18.2-positive Advanced Digestive Tract Tumor.
- Trial name
- NCT05934331
- Testing
- LM-302, Toripalimab, Capecitabine
- Where
- China
- Volunteers
- 632 people
- Sponsor
- LaNova Medicines Zhejiang Co., Ltd.
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJC
The goal of this exploratory study is to evaluate the efficacy and safety of zeprumetostat in combination with retlirafusp alfa, apatinib, and chemotherapy as first-line treatment in patients with HER2-negative unresectable…
- Trial name
- NCT07874425
- Testing
- Retlirafusp alfa, zeprumetostat, apatinib
- Volunteers
- 55 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC
This study intends to prospectively enroll CNLC stage IIIb HCC cases with extrahepatic metastasis and intrahepatic lesions that are expected to be radical resected in several domestic clinical centers, and observe the OS and ORR…
- Trial name
- NCT05062837
- Testing
- Hepatectomy Combined With Camrelizumab and Apatinib
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma(HCC)
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
This project is a prospective, multi-center, multi-cohort exploratory clinical study. It focuses on patients with advanced hepatocellular carcinoma who experience disease progression after first-line standard therapy.
- Trial name
- ICT-HCC (NCT06893887)
- Testing
- FOLFOX4, Adebrelimab, Apatinib
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Nanjing Tianyinshan Hospital
Small Cell Lung Cancer Limited Stage
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
This is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer.
- Trial name
- NCT06483282
- Testing
- Adebrelimab, Apatinib Mesylate, Etoposide
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Jin Ying
Gastric Cancer, Apatinib
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
The study is to investigate the efficacy and safety of apatinib for the first-fine treatment in elderly patients with locally advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction, unable or unwilling to…
- Conditions
- Gastric Cancer, Apatinib, Biomarker
- Trial name
- NCT03219593
- Testing
- Apatinib mesylate tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Triple-negative Breast Cancer
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
This is a prospective, randomized, open-label clinical study. 128 patients with relapsed or metastatic triple-negative breast cancer (TNBC) who had not been systematically treated are going to be enrolled and randomly assigned to…
- Trial name
- NCT05192798
- Testing
- Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab
- Where
- China
- Volunteers
- 128 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Malignant Ascites, Apatinib
A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
Malignant ascites is a severe complication of many types of human cancer. Animal and clinical analyses have shown that angiogenesis plays a critical role in the formation of malignant ascites.
- Trial name
- NCT03020979
- Testing
- Apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC
The goal of this clinical trial is to evaluate the safety and efficacy of GnP combined with SHR-1701 and Apatinib as first-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
- Trial name
- NCT07802184
- Testing
- SHR-1701, Apatinib, gemcitabine
- Where
- China
- Volunteers
- 45 people
- Sponsor
- West China Hospital
Advanced Gastric Cancer, SHR1701
PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach.
- Trial name
- NCT07294664
- Testing
- SHR1701, SHR2554, CAPOX
- Where
- China
- Volunteers
- 78 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Liver Cancer
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular Invasion
A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Targeted Therapy and a PD-1 Inhibitor in Patients with Postoperative Hepatocellular Carcinoma…
- Trial name
- NCT07790419
- Testing
- HAIC, Donafenib + lenvatinib+apatinib, Sintilimab+camrelizumab+tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhai Wenlong
Pancreatic Cancer
Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer
This is a prospective, open-label, single-arm clinical study designed to evaluate the efficacy and safety of retlirafusp alfa combined with apatinib and chemotherapy as second-line treatment in patients with unresectable locally…
- Trial name
- NCT07773363
- Testing
- Retlirafusp Alfa, Apatinib, Fluoropyrimidine-Based Chemotherapy
- Volunteers
- 37 people
- Sponsor
- Tang-Du Hospital
GC/GEJC
A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer
This study is a prospective, randomized, non-controlled, open-label clinical trial aimed at evaluating the efficacy and safety of adebrelimab combined with apatinib mesylate and albumin-bound paclitaxel, as well as apatinib…
- Trial name
- NCT07770113
- Testing
- Adebrelimab, Apatinib, Albumin-bound paclitaxel
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Advanced Unresectable Hepatocellular Carcinoma
SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma
This clinical study aims to evaluate the efficacy and safety of Retlirafusp alfa Injection (SHR-1701) combined with apatinib in patients with advanced hepatocellular carcinoma (HCC) who have experienced disease progression after…
- Trial name
- NCT07749859
- Testing
- Retlirafusp alfa Injection, apatinib
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Potentially Resectable Hepatocellular Carcinoma
Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
The purpose of this phase 2/3 study is to investigate the efficacy and safety of camrelizumab combined with rivoceranib and hepatic arterial infusion chemotherapy (HAIC) as conversion therapy for Potentially Resectable HCC.
- Trial name
- NCT06796803
- Testing
- camrelizumab combined with rivoceranib and HAIC, camerlizumab + rivoceranib
- Where
- 2 sites in China
- Volunteers
- 398 people
- Sponsor
- Shanghai Zhongshan Hospital